News Notable Labs, Ltd.

Equities

NTBL

IL0012002452

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-04-11 pm EDT			5-day change	1st Jan Change
1.16 ^USD	-4.13%		-22.15%	-38.62%

Apr. 15	Chardan Cuts Price Target on Notable Labs to $7 From $9, Keeps Buy Rating	MT
Apr. 15	Chardan Cuts Price Target on Notable Labs to $7 From $9 on Higher Projected Future Share Count, Keeps Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Notable Labs Reports 2023 Financial Results and Provides a Business Update	Apr. 15	AQ
Chardan Cuts Price Target on Notable Labs to $7 From $9, Keeps Buy Rating	Apr. 15	MT
Chardan Cuts Price Target on Notable Labs to $7 From $9 on Higher Projected Future Share Count, Keeps Buy Rating	Apr. 15	MT
Notable Labs Reports 2023 Financial Results and Provides a Business Update	Apr. 12	AQ
VASR BIOG : AACR 2024 VOLA Poster	Apr. 09	PU
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024	Apr. 09	AQ
Notable Labs, Ltd. Presents the Design Plan for the Ppmp-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024	Apr. 09	CI
VASR BIOG : AACR 2024 Poster	Apr. 08	PU
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform	Apr. 08	AQ
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay At AACR 2024 Expands the Potential of the Platform	Apr. 08	CI
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform	Mar. 05	AQ
Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment	Feb. 22	AQ
Notable Labs, Ltd. Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment	Feb. 22	CI
Top Premarket Gainers	Jan. 09	MT
JMP Securities Cuts Notable Labs' Price Target to $9 From $13, Keeps Market Outperform Rating	Dec. 19	MT
Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome	Dec. 18	AQ
Notable Labs, Ltd. and CicloMed LLC Announces Initial Safety and Efficacy Data of Fosciclopirox and the Performance of PPMP	Dec. 18	CI
Notable Labs to Participate in JMP Securities Hematology and Oncology Summit	Dec. 04	AQ
Notable Labs Announces Filing of Form 10-Q for Third Quarter 2023	Nov. 14	AQ
Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML	Nov. 09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Notable Labs, Ltd.

Equities

NTBL

IL0012002452

Summary

Filters